Table 1.
Demographic and drug details of PD Patients and controls
No | Sex | Age | Sw- En | HY Off | HY On | UPDRS Off | UPDRS On | Years (diagnosis) | L-dopa mg/d | L-dopa equivalent1 | Nart error | Predicted FullScale IQ | MM SE | Fluency |
Medications (mg) |
|||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P | Animals | A | C | R | E | Other | ||||||||||||||
1 | F | 53 | 80 | 2 | 2 | 24 | 14 | 8.7 | 900 | 2200 | 6 | 123 | 30 | 20 | 28 | 100 | 21 | |||
2 | M | 61 | 70 | 4 | 2 | 53 | 17 | 15.4 | 2200 | 2585 | 5 | 124 | 30 | 24 | 24 | 300 | T 300 | |||
3 | M | 78 | 80 | 4 | 3 | 50 | 30 | 13.5 | 700 | 512 | 29 | 104 | 25 | 13 | 20 | O 120 | ||||
4 | F | 65 | 100 | 2 | 2 | 12 | 7 | 5.0 | 250 | 1090 | 30 | 103 | 30 | 17 | 24 | 21 | O 50, D 30 | |||
5 | M | 65 | 70 | 2.5 | 2.5 | 36 | 19 | 13.5 | 700 | 1196 | 36 | 98 | 27 | 22 | 25 | 800 | S 10 | |||
6 | F | 50 | 90 | 2.5 | 2 | 34 | 15 | 9.5 | 300 | 1200 | 27 | 105 | 27 | 11 | 19 | 200 | 15 | |||
7 | F | 78 | 90 | 2 | 1 | 14 | 1 | 5.7 | 600 | 600 | 28 | 105 | 29 | 12 | 17 | |||||
8 | M | 64 | 90 | 2 | 2 | 20 | 17 | 3.0 | 400 | 1290 | 5 | 124 | 30 | 19 | 28 | 100 | P 2.1 | |||
9 | M | 69 | 80 | 2 | 2 | 29 | 18 | 4.8 | 400 | 1120 | 45 | 91 | 29 | 10 | 19 | 4 | S 1.25 | |||
10 | F | 65 | 90 | 3 | 2.5 | 38 | 30 | 4.6 | 600 | 1560 | 32 | 101 | 27 | 6 | 20 | 24 | ||||
11 | M | 59 | 80 | 2.5 | 2 | 36 | 29 | 5.7 | 500 | 1140 | 13 | 117 | 30 | 23 | 24 | 200 | 4 | |||
12 | F | 59 | 70 | 2.5 | 2 | 34 | 31 | 5.5 | 300 | 1260 | 12 | 118 | 30 | 31 | 35 | 6 | ||||
13 | M | 68 | 80 | 2.5 | 2 | 32 | 20 | 9.0 | 250 | 915 | 33 | 100 | 28 | 9 | 11 | 4 | S 5 | |||
14 | M | 66 | 80 | 2.5 | 2 | 33 | 25 | 6.9 | 800 | 1009 | 37 | 97 | 26 | 11 | 16 | 200 | 1 | 600 | ||
15 | F | 75 | 80 | 2.5 | 2 | 34 | 26 | 10.7 | 1200 | 1745 | 2 | 127 | 27 | 23 | 17 | 200 | 18 | 800 | ||
16 | F | 62 | 90 | 3 | 1 | 26 | 10 | 5.4 | 500 | 1020 | 42 | 93 | 29 | 21 | 12 | 18 | 600 | |||
17 | M | 62 | 100 | 2.5 | 2 | 30 | 19 | 5.2 | 800 | 1640 | 42 | 93 | 28 | 8 | 24 | 100 | P 1 | |||
18* | M | 75 | 70 | 3 | 2 | 32 | 22 | 5.6 | 1300 | 1475 | 15 | 115 | 26 | 18 | 16 | 9 | ||||
19** | M | 63 | 70 | 2.5 | 2 | 39 | 14 | 10.1 | 600 | 1680 | 12 | 118 | 29 | 12 | 24 | 200 | 24 | 800 | ||
Patients | ||||||||||||||||||||
11m | Mean | 65.1 | 82.1 | 2.6 | 2.0 | 31.9 | 19.2 | 7.8 | 700.0 | 1328.3 | 23.7 | 108.2 | 28.3 | 16.3 | 21.2 | |||||
8 f | SD | 7.7 | 9.8 | 0.4 | 0.5 | 10.2 | 8.2 | 3.5 | 467.6 | 502.7 | 14.2 | 11.9 | 1.6 | 6.7 | 5.9 | |||||
Controls | ||||||||||||||||||||
8 m | Mean | 67.4 | 14 | 116 | 29.1 | 16.1 | 21.8 | |||||||||||||
9 f | SD | 6.1 | 7.2 | 6 | 0.8 | 4.6 | 5 |
1Equivalent levodopa dose = [levodopa (× 1.2 if COMT inhibitor)(× 1.2 if 10 mg of S or × 1.1 if 5 mg of S)] + [P × 400] + [R × 40] + [C × 160] + [pergolide × 200] + [bromocriptine × 10] + [lisuride × 160]; all doses are in milligrams. [Williams Gray C. J Neurosci 2007 27 4832–38]. *arachnoid cyst, excluded from imaging analysis, SwEn = Schwab and England; H Y = Hoehn and Yahr; UDPRS = Unified Parkinson's Disease Rating Scale motor subscale III; MMSE = Folstein Mini-Mental State Examination; NART = national adult reading test estimate of premorbid IQ. **dyskinetic ‘on’, excluded from imaging analysis. Other drugs as mg/day are: A = amantadine; C = Cabergoline; R = Ropinirole; E = entacapone; T = tolcapone; S = selegiline; P = pramipexole; O = orphenadrine, D = domperidone.